Full metadata record

DC FieldValueLanguage
dc.contributor.author최원일-
dc.date.accessioned2017-08-08T08:44:10Z-
dc.date.available2017-08-08T08:44:10Z-
dc.date.issued2012-
dc.identifier.citationKeimyung Medical Journal, Vol.31(1) : 36-44, 2012-
dc.identifier.otherKMJ-2012-004-
dc.identifier.urihttp://kumel.medlib.dsmc.or.kr/handle/2015.oak/15552-
dc.description.abstractLast 20 years, great progress has been made in the care of advanced non-small cell lung cancer, especially adenocarcinoma. One year survival of advanced non-small cell lung cancer increases from 30% to 55%. Third-generation regimens with or without front-line targeted agents, or with efficient second- and third line low toxicity therapies may contribute improving survival. The emergence of targeted therapy in first- and second-line settings has spectacularly changed the natural history of disease especially EGFR mutated cancer, leading to dramatically prolonged overall survival. Maintenance therapy, either with targeted agents or cytotoxic agents, also improved survival for larger groups of non-small cell lung cancer.-
dc.description.statementofresponsibilityopen-
dc.publisherKeimyung University School of Medicine-
dc.rightsBY_NC_ND-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.0/kr-
dc.subjectAdenocarcinoma-
dc.subjectNonsmall cell lung cancer-
dc.subjectTargeted therapy-
dc.title폐암 치료의 최신 지견, 폐선암을 중심으로-
dc.title.alternativeUpdate on Lung Cancer Treatment Focused on Adenocarcinoma-
dc.typeArticle-
dc.contributor.alternativeauthorWon-Il Choi-
dc.contributor.localauthor최원일-
dc.contributor.alternativelocalauthorChoi, Won Il-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.citation.volume31-
dc.citation.number1-
dc.citation.startpage36-
dc.citation.titleKeimyung Medical Journal-
dc.citation.endpage44-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE